 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || rasagiline prodrug (HNC364) / Henovcom
Trial completion: A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - Sep 27, 2024
P1, N=34, Completed, Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.
Recruiting --> Completed
- | rasagiline prodrug (HNC364) / Henovcom
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - Mar 21, 2024
P1, N=34, Recruiting, Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.
Recruiting --> Completed Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Sep 2023 --> Apr 2024
- || rasagiline prodrug (HNC364) / Henovcom
Enrollment change: A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - Aug 1, 2023
P1, N=34, Recruiting, Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.
Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Sep 2023 --> Apr 2024 N=18 --> 34
- | rasagiline prodrug (HNC364) / Henovcom
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - Jul 31, 2023
P1, N=18, Recruiting, Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.
N=18 --> 34 Trial completion date: Apr 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Sep 2023
- || rasagiline prodrug (HNC364) / Henovcom
New P1 trial: A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - Aug 31, 2022
P1, N=18, Recruiting, Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.